Evaluating the effectiveness and cost-effectiveness of Tobacco Cessation services in Swedish primary healthcare targeting socioeconomically disadvantaged areas in Stockholm - the "Motivation 2 Quit" (M2Q) study

Evaluating the effectiveness and cost-effectiveness of Tobacco Cessation on Prescription in Swedish primary healthcare targeting socioeconomically disadvantaged areas in Stockholm - the "Motivation 2 Quit" (M2Q) study, a cluster-randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN11498135

Enrollment

860

Registered

2016-01-11

Start date

2016-02-01

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking Mental and Behavioural Disorders

Interventions

Participants are randomly allocated to either tobacco cessation on prescription or standard treatment according to which primary healthcare centre (PHC) they attend. 1. Tobacco cessat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Swedish or Arabic speaking daily tobacco users with Swedish social security number and permanent resident permit 2. Over 18 years of age 3. Visiting participating primary health care centres in the study

Exclusion criteria

Exclusion criteria: 1. Ongoing treatment for tobacco cessation 2. Cognitive impairment affecting ability to participate in the study on a voluntary basis

Design outcomes

Primary

Measure	Time frame
Point prevalence of 7-day abstinence (total abstinence from tobacco use during the 7 days preceding follow-up) at 6 months after the intervention	—

Secondary

Measure	Time frame
1. Point prevalence of 7-day abstinence at 12 months after the intervention 2. Daily tobacco consumption (number of cigarettes), at 6 and 12 months after the intervention 3. Number of quit attempts and health-related quality of life (on a scale from 0-1 where 0 represents death and 1 represents perfect health) at 6 and 12 months after the intervention 4. Cost effectiveness, measured as the incremental cost per quality-adjusted life year All outcomes will be based on self-reports from patient questionnaires.	—

Measure

Time frame

1. Point prevalence of 7-day abstinence at 12 months after the intervention 2. Daily tobacco consumption (number of cigarettes), at 6 and 12 months after the intervention 3. Number of quit attempts and health-related quality of life (on a scale from 0-1 where 0 represents death and 1 represents perfect health) at 6 and 12 months after the intervention 4. Cost effectiveness, measured as the incremental cost per quality-adjusted life year All outcomes will be based on self-reports from patient questionnaires.

—

Countries

Sweden

Contacts

Public ContactAnne Leppänen

anne.leppanen@ki.se+46 (0)852 483 612

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 1, 2026